• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The prostate: an increasing medical problem.

作者信息

Carter H B, Coffey D S

机构信息

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

出版信息

Prostate. 1990;16(1):39-48. doi: 10.1002/pros.2990160105.

DOI:10.1002/pros.2990160105
PMID:1689482
Abstract

The prostate gland is the major site of medical problems in the U.S. male. Surgery for benign prostatic hyperplasia is the most common surgical procedure performed in males, and the total cost for this surgery exceeds 1 billion dollars per year. The incidence of and mortality from prostate cancer are increasing yearly. Prostate cancer now exceeds lung cancer as the most commonly diagnosed cancer in males and is the second leading cause of male cancer deaths. Of all tumors, the prevalence of prostate cancer increases the most rapidly with age. A shift in age distribution favoring an older population will lead to an increase in the number of patients diagnosed with prostate cancer in the United States. It is estimated that by the year 2000 there will be a 37% increase in prostate cancer deaths per year and a 90% increase in prostate cancer cases per year. Although the factors responsible for the development and progression of prostate cancer to a clinically manifest form are not known, there is evidence that environmental factors may play a role. It will be important for the future to focus on the etiological factors that may lead to a decrease in the prevalence of prostatic tumors.

摘要

相似文献

1
The prostate: an increasing medical problem.
Prostate. 1990;16(1):39-48. doi: 10.1002/pros.2990160105.
2
Epidemiologic evidence regarding predisposing factors to prostate cancer.关于前列腺癌诱发因素的流行病学证据。
Prostate. 1990;16(3):187-97. doi: 10.1002/pros.2990160302.
3
Benign prostatic hyperplasia, prostate cancer and other prostate diseases diagnosed as a result of screening procedure among 1,004 men in the Lublin district.在卢布林地区的1004名男性中,通过筛查程序诊断出的良性前列腺增生、前列腺癌及其他前列腺疾病。
Ann Univ Mariae Curie Sklodowska Med. 2002;57(1):493-501.
4
Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.经计算的快速增长型良性前列腺增生——一种发生临床前列腺癌的风险因素。
Scand J Urol Nephrol. 2002;36(5):330-8. doi: 10.1080/003655902320783827.
5
Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China.中国良性前列腺增生症和前列腺癌发病率的初步研究
Urology. 1994 Nov;44(5):688-91. doi: 10.1016/s0090-4295(94)80207-6.
6
[Adenocarcinoma of the prostate].前列腺腺癌
Cas Lek Cesk. 1998 Aug 31;137(17):515-21.
7
Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China.中国上海的前列腺癌、良性前列腺增生与身体活动
Int J Epidemiol. 2001 Apr;30(2):341-9. doi: 10.1093/ije/30.2.341.
8
New insights into the epidemiology and natural history of benign prostatic hyperplasia.良性前列腺增生症流行病学及自然史的新见解
Prog Clin Biol Res. 1994;386:3-18.
9
[Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma].老年患者的前列腺疾病。良性前列腺增生和前列腺癌
Wien Med Wochenschr. 2001;151(18-20):430-8.
10
The association of benign prostatic hyperplasia and cancer of the prostate.良性前列腺增生与前列腺癌的关联。
Cancer. 1992 Jul 1;70(1 Suppl):291-301. doi: 10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4.

引用本文的文献

1
The Role and Significance of Bioumoral Markers in Prostate Cancer.生物标志物在前列腺癌中的作用及意义
Cancers (Basel). 2021 Nov 25;13(23):5932. doi: 10.3390/cancers13235932.
2
New benzothieno[2,3-]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and ADME profile studies.新型苯并噻吩[2,3-d]吡啶类非甾体 CYP17 抑制剂的设计、合成、抗癌活性筛选、诱导细胞凋亡及 ADME 性质研究。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1839-1859. doi: 10.1080/14756366.2021.1958212.
3
The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions.
前列腺特异性抗原速度(PSAV)、数值及增速与游离前列腺特异性抗原/总前列腺特异性抗原指数或比值与前列腺疾病之间的关联。
J Clin Med. 2020 Oct 23;9(11):3400. doi: 10.3390/jcm9113400.
4
Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention.α-肾上腺素能受体拮抗剂对前列腺癌发生、发展及预防的影响。
Am J Clin Exp Urol. 2019 Feb 18;7(1):46-60. eCollection 2019.
5
Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis.格列吡嗪通过抑制血管生成抑制 TRAMP 模型中的前列腺癌进展。
Sci Rep. 2016 Jun 13;6:27819. doi: 10.1038/srep27819.
6
Outcome of transurethral plasmakinetic vaporization for benign prostatic hyperplasia.经尿道等离子体动能汽化术治疗良性前列腺增生症的疗效
Int Braz J Urol. 2015 Mar-Apr;41(2):239-44. doi: 10.1590/S1677-5538.IBJU.2015.02.08.
7
Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family.薯蓣皂苷通过激活半胱天冬酶-3和调节Bcl-2蛋白家族诱导人LNCaP前列腺癌细胞凋亡。
J Huazhong Univ Sci Technolog Med Sci. 2014 Feb;34(1):125-130. doi: 10.1007/s11596-014-1243-y. Epub 2014 Feb 6.
8
Nanostructured systems containing babassu (Orbignya speciosa) oil as a potential alternative therapy for benign prostatic hyperplasia.含有巴巴苏(Orbignya speciosa)油的纳米结构系统作为治疗良性前列腺增生的潜在替代疗法。
Int J Nanomedicine. 2013;8:3129-39. doi: 10.2147/IJN.S47731. Epub 2013 Aug 15.
9
Loss of P53 facilitates invasion and metastasis of prostate cancer cells.P53 的缺失促进了前列腺癌细胞的侵袭和转移。
Mol Cell Biochem. 2013 Dec;384(1-2):121-7. doi: 10.1007/s11010-013-1789-1. Epub 2013 Aug 28.
10
Age-related histological and zinc content changes in adult nonhyperplastic prostate glands.成年非增生性前列腺腺体中与年龄相关的组织学和锌含量变化。
Age (Dordr). 2014 Feb;36(1):167-81. doi: 10.1007/s11357-013-9561-8. Epub 2013 Jul 14.